Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark office (USPTO) has issued a composition-of-matter patent to Zalicus for Synavive.
Subscribe to our email newsletter
Zalicus said that the US patent no. 7,915,265 entitled ‘Combinations for the Treatment of Immunoinflammatory Disorders’ offers coverage for Synavive through August 2025.
Synavive is indicated for the treatment of rheumatoid arthritis.
The drug has demonstrated anti-inflammatory effects, rapid onset of action and tolerable safety profiles in clinical studies in rheumatoid arthritis and hand and knee osteoarthritis.
The company said that the key patent, along with the existing issued method-of-use patent (US patent 7,253,155), fortifies the Synavive patent estate, which includes several patents and patent applications, granted and pending worldwide which collectively provide coverage of Synavive through at least 2028.
Zalicus president and CEO Mark HN Corrigan said these two key patents provide the foundation of a solid and enforceable intellectual property estate for Synavive, with issued claims through 2025, and pending applications around our proprietary formulations providing coverage into 2028.